TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Is it possible to use different BCMA-targeted agents successively?

Featured:

María-Victoria MateosMaría-Victoria Mateos

Sep 16, 2022

Learning objective: After reading this article, learners will be able to cite a new clinical development in relapsed/refractory MM


During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to María-Victoria Mateos , University Hospital of Salamanca, Salamanca, ES. We asked, Is it possible to use different B-cell maturation antigen (BCMA)-targeted agents successively?

Is it possible to use different BCMA-targeted agents successively?

In this video, Mateos discusses the clinical outcomes of a cohort of 20 patients treated with different BCMA-targeted therapies sequentially. Mateos evaluates these outcomes in terms of minimal residual disease negativity rate, progression-free survival, and safety signals to come to a conclusion on the posed question.